Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...
Stocktwits on MSN6d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers
Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Investing2d
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen
On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response Letter (CRL ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
MPR2d
FDA Decision on Etripamil Nasal Spray Delayed Due to Nonclinical Issues
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...